NCT02048865View on ClinicalTrials.gov

Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

575

Participants

Timeline

Start Date

March 24, 2014

Primary Completion Date

October 10, 2018

Study Completion Date

October 19, 2018

Conditions
Venous ThromboembolismCancer
Interventions
DRUG

Apixaban

Apixaban 2.5 mg tablets BID for 6 months

DRUG

Placebo drug

placebo drug 2.5mg BID for 6 months

Trial Locations (14)

V5Z 1M9

Vancouver General Hospital, Vancouver

B3H 1V7

Capital District Health Authority, Halifax

L4M 6M2

Royal Victoria Regional Health Centre (RVH), Barrie

L6R 3J7

William Osler Health System -Brampton, Brampton

L8V 1C3

Juravinski Hospital & Cancer Centre, Hamilton

K7L 2V7

Kingston General Hospital, Kingston

N6A 5W9

London Health Sciences Center, London

Unknown

Lakeridge Health -Oshawa, Oshawa

Centre intégré de santé et de services sociaux du Bas St Laurent -Rimouski, Rimouski

K1H 8L6

Ottawa Hospital-General Campus, Ottawa

P6B 0A8

Sault Area Hospital, Sault Ste. Marie

L3P 7P3

Markham Stouffville Hospital, Toronto

J8P 7H2

Centre intégré de santé et de services sociaux de l'Outaouais - Gatineau, Gatineau

H3T 1E2

Jewish General Hospital, Montreal

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Ottawa Hospital Research Institute

OTHER